RAF-MEK-ERK pathway in cancer evolution and treatment

Cites (506)

Items 401–489 of 489

1. ERK Regulates HIF1α-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer
   Zhuqing Li, Wei Zhou, Yi Zhang, Wei Sun, Mingo M. H. Yung, Jing Fang Sun, Jing Li, Chi‐Wei Chen, Zongzhu Li, Yunxiao Meng et al. · 2019 · Clinical Cancer Research
2. Protein-tyrosine-phosphatase 2C is phosphorylated and inhibited by 44-kDa mitogen-activated protein kinase.
   Pascal Peraldi, Zhizhuang Zhao, Chantal Filloux, Edmond H. Fischer, Emmanuel VAN OBBERGHEN · 1994 · Proceedings of the National Academy of Sciences
3. Ro 09-2210 Exhibits Potent Anti-proliferative Effects on Activated T Cells by Selectively Blocking MKK Activity
   D. H. Williams, Sandra E. Wilkinson, T Purton, Alan G. Lamont, Horst Flotow, Edward J. Murray · 1998 · Biochemistry
4. CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity
   Joyce James, Bruce R. Ruggeri, Robert C. Armstrong, Martin W. Rowbottom, Susan Jones‐Bolin, Ruwanthi N. Gunawardane, Paweł Dobrzański, Michael F. Gardner, Hugh Q. Zhao, Merryl D. Cramer et al. · 2012 · Molecular Cancer Therapeutics
5. Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination
   Pierre Mordant, Yohann Loriot, Céline Leteur, Julien Caldéraro, Jean Bourhis, Marie Wislez, Jean‐Charles Soria, Éric Deutsch · 2010 · Molecular Cancer Therapeutics
6. RSK2 as a key regulator in human skin cancer
   Yong‐Yeon Cho, Mee‐Hyun Lee, Cheol‐Jung Lee, Ke Yao, Hye Suk Lee, Ann M. Bode, Zigang Dong · 2012 · Carcinogenesis
7. Phosphorylation and Activation of the ATP-Mg-dependent Protein Phosphatase by the Mitogen-activated Protein Kinase
   Q. May Wang, Kun‐Liang Guan, Peter J. Roach, Anna A DePaoli-Roach · 1995 · Journal of Biological Chemistry
8. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression
   Manali S. Phadke, Patrizia Sini, Keiran S.M. Smalley · 2015 · Molecular Cancer Therapeutics
9. Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers
   Gisele Nishiguchi, Alice C. Rico, Huw R. Tanner, Robert J. Aversa, Benjamin R. Taft, Sharadha Subramanian, L Setti, Matthew T. Burger, Lifeng Wan, Victoriano Tamez et al. · 2017 · Journal of Medicinal Chemistry
10. EGFR and FGFR Signaling through FRS2 Is Subject to Negative Feedback Control by ERK1/2
    Yuanyuan Wu, Zhi Chen, Axel Ullrich · 2003 · Biological Chemistry
11. Serine 111 Phosphorylation Regulates OCT4A Protein Subcellular Distribution and Degradation
    Renza Spelat, Federico Ferro, Francesco Curcio · 2012 · Journal of Biological Chemistry
12. Raf kinases mediate the phosphorylation of eukaryotic translation elongation factor 1A and regulate its stability in eukaryotic cells
    Carmen Sanges, C Scheuermann, René Peiman Zahedi, Albert Sickmann, Annalisa Lamberti, Nunzia Migliaccio, Angela Baljuls, Monica Marra, Silvia Zappavigna, Jörg Reinders et al. · 2012 · Cell Death and Disease
13. A Systems Perspective of Ras Signaling in Cancer
    Edward C. Stites, Kodi S. Ravichandran · 2009 · Clinical Cancer Research
14. Extracellular Signal-regulated Kinase Activated by Epidermal Growth Factor and Cell Adhesion Interacts with and Phosphorylates Vinexin
    Masaru Mitsushima, Akira Suwa, Teruo Amachi, Kazumitsu Ueda, Noriyuki Kioka · 2004 · Journal of Biological Chemistry
15. Mitogen-activated Protein Kinase Phosphorylates and Targets Inducible cAMP Early Repressor to Ubiquitin-mediated Destruction
    Ghassan Yehia, Florence Schlotter, Reza Razavi, Alessandro Alessandrini, Carlos Augusto Fernandes Molina · 2001 · Journal of Biological Chemistry
16. The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis
    Bjoern Buchholz, Bernd Klanke, Gunnar Schley, Gideon E. Bollag, James Y. Tsai, Sven Kroening, Daisuke Yoshihara, Darren P. Wallace, Bettina Kraenzlin, N. Gretz et al. · 2011 · Nephrology Dialysis Transplantation
17. Negative feedback loop in T‐cell activation through MAPK‐catalyzed threonine phosphorylation of LAT
    Satoshi Matsuda, Yoshihiro Miwa, Yasuko Hirata, Akiko Minowa, Junko Tanaka, Eisuke Nishida, Shigeo Koyasu · 2004 · The EMBO Journal
18. p90 ribosomal S6 kinase: a potential therapeutic target in lung cancer
    Noufira Poomakkoth, Aya Issa, Nabeel Abdulrahman, Somaia Abdelaziz, Fatima Mraiche · 2016 · Journal of Translational Medicine
19. Crystal structure of ERK2 G169D mutant
    J. Yin, Bijay Shankar Jaiswal, W. Wang · 2018 · Worldwide Protein Data Bank
20. A new ERK2 binding protein, Naf1, attenuates the EGF/ERK2 nuclear signaling
    Shengliang Zhang, Masaya Fukushi, Shinichi Hashimoto, Chongfeng Gao, Lin Huang, Yayoi Fukuyo, Takuma Nakajima, Teruo Amagasa, Shoji ENOMOTO, Katsuro Koike et al. · 2002 · Biochemical and Biophysical Research Communications
21. SEL-10/Fbw7-dependent negative feedback regulation of LIN-45/Braf signaling in C. elegans via a conserved phosphodegron
    Claire de la Cova, Iva Greenwald · 2012 · Genes & Development
22. Structural snapshots of RAF kinase interactions
    Soheila Rezaei Adariani, Marcel Buchholzer, Mohammad Akbarzadeh, Saeideh Nakhaei‐Rad, Radovan Dvorský, Mohammad Reza Ahmadian · 2018 · Biochemical Society Transactions
23. p90RSK2 is essential for FLT3-ITD– but dispensable for BCR-ABL–induced myeloid leukemia
    Shannon Elf, Dean P. Blevins, Lingtao Jin, Tae‐Wook Chung, Ifor R. Williams, Benjamin H. Lee, Jian‐Xin Lin, Warren J. Leonard, Jack Taunton, Hanna Jean Khoury et al. · 2011 · Blood
24. Exceptionally high-affinity Ras binders that remodel its effector domain
    John H. McGee, So Youn Shim, Seung‐Joo Lee, Paige K. Swanson, Sam Y. Jiang, Michael A. Durney, Gregory L. Verdine · 2017 · Journal of Biological Chemistry
25. Extracellular Signal-Regulated Kinase (ERK) Inhibitors in Oncology Clinical Trials
    Haelee M. Chin, David K Lai, Gerald Steven Falchook · 2019 · Journal of Immunotherapy and Precision Oncology
26. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial
    Yan-Song Lin, Hui Yang, Yong Jie Ding, Yizhuang Cheng, Feng Shi, Jian Tan, Zhiyong Deng, Zhendong Chen, Rongfu Wang, Qinghai Ji et al. · 2020 · Thyroid
27. AMPK Promotes Aberrant PGC1β Expression To Support Human Colon Tumor Cell Survival
    Kurt W. Fisher, Binita Das, Hyun Seok Kim, Beth K. Neilsen, Drew Gehring, Deandra R. Smith, Diane L. Costanzo-Garvey, Mario R. Fernandez, Michael G. Brattain, David L. Kelly et al. · 2015 · Molecular and Cellular Biology
28. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors
    Dan M. Berger, Nancy Torres, Minu D. Dutia, Dennis W. Powell, Greg Ciszewski, Ariamala Gopalsamy, Jeremy I. Levin, Kyung‐Hee Kim, Weixin Xu, James Wilhelm et al. · 2009 · Bioorganic & Medicinal Chemistry Letters
29. The E3 ubiquitin ligase HERC1 controls the ERK signaling pathway targeting C-RAF for degradation
    Taiane Schneider, Arturo Martinez-Martinez, Monica Cubillos‐Rojas, Ramón Bartrons, Francesc Ventura, José Luís Rosa · 2018 · Oncotarget
30. Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance
    Ida Aronchik, Yumin Dai, Matthew Labenski, Carmen Barnes, Terri Jones, Lixin Qiao, Lisa Beebe, Mehnaz Malek, Winfried Elis, Tao Shi et al. · 2018 · Molecular Cancer Research
31. Rab4 is phosphorylated by the insulin‐activated extracellular‐signal‐regulated kinase ERK1
    Mireille Cormont, Jean‐François Tanti, Ahmed Zahraoui, Emmanuel VAN OBBERGHEN, Yannick LE MARCHAND‐BRUSTEL · 1994 · European Journal of Biochemistry
32. Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor
    Patrice A. Lee, Eli M. Wallace, Allison Marlow, Tammie C. Yeh, Vivienne Marsh, Deborah A. Anderson, Richard D. Woessner, Brian Hurley, Joseph P. Lyssikatos, Gregory Poch et al. · 2010 · Cancer Research
33. BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
    Nicholas Theodosakis, Matthew A. Held, Alexander Marzuka-Alcalá, Katrina M. Meeth, Goran Micevic, Georgina Venetia Long, Richard A. Scolyer, David F. Stern, Marcus Bosenberg · 2015 · Molecular Cancer Therapeutics
34. Cutting edge: extracellular signal-regulated kinase activates syk: a new potential feedback regulation of Fc epsilon receptor signaling.
    R.X. Xu, Rony Seger, Israel Pecht · 1999 · PubMed
35. Ras/ERK-signalling promotes tRNA synthesis and growth via the RNA polymerase III repressor Maf1 in Drosophila
    Shrivani Sriskanthadevan-Pirahas, Rujuta Deshpande, Byoungchun Lee, Savraj Grewal · 2018 · PLoS Genetics
36. Cutting Edge: Extracellular Signal-Regulated Kinase Activates Syk: A New Potential Feedback Regulation of Fcε Receptor Signaling
    Rong Xu, Rony Seger, Israel Pecht · 1999 · The Journal of Immunology
37. Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors
    Alexandra E. Gould, Ruth Adams, Sharmila Adhikari, Kathleen Aertgeerts, Roushan Afroze, Christopher Blackburn, Emily F. Calderwood, Ryan Chau, Jouhara Chouitar, Matthew O. Duffey et al. · 2011 · Journal of Medicinal Chemistry
38. Mitogen-activated Protein Kinase Kinase 1 (MEK1) Stabilizes MyoD through Direct Phosphorylation at Tyrosine 156 During Myogenic Differentiation
    Chulman Jo, Sun‐Jung Cho, Sangmee Ahn Jo · 2011 · Journal of Biological Chemistry
39. Intramolecular Dephosphorylation of ERK by MKP3
    Young‐Joo Kim, Adrian E. Rice, John M. Denu · 2003 · Biochemistry
40. Arginase II activity regulates cytosolic Ca2+ level in a p32-dependent manner that contributes to Ca2+-dependent vasoconstriction in native low-density lipoprotein-stimulated vascular smooth muscle cells
    Bon‐Hyeock Koo, Dongeui Hong, Hyeon Hong, Hyun Kyo Lim, Kwang‐Lae Hoe, Moo‐Ho Won, Young‐Myeong Kim, Dan E. Berkowitz, Sungwoo Ryoo · 2019 · Experimental & Molecular Medicine
41. ERK-dependent phosphorylation of the linker and substrate-binding domain of HSP70 increases folding activity and cell proliferation
    Semi Lim, Dae Gyu Kim, Sung‐Hoon Kim · 2019 · Experimental & Molecular Medicine
42. Destabilization of KLF10, a tumor suppressor, relies on thr93 phosphorylation and isomerase association
    Yu‐Chyi Hwang, Chien-Hui Yang, Ching-Hui Lin, Hui-Ju Ch'ang, Vincent H.S. Chang, Wenyu Yu · 2013 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
43. Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors
    Mark Andrew Dickson, Michael S. Gordon, Gerald M. Edelman, Johanna C. Bendell, Ragini Reiney Kudchadkar, Patricia Mucci LoRusso, Stuart H. Johnston, Douglas O. Clary, Gary K. Schwartz · 2014 · Investigational New Drugs
44. Functional Interactions of Raf and MEK with Jun-N-Terminal Kinase (JNK) Result in a Positive Feedback Loop on the Oncogenic Ras Signaling Pathway
    Victor Adler, Yongxia Sarah Qu, Steven J. Smith, Lara S. Izotova, Sidney Pestka, Hsiang‐Fu Kung, Marie C.M. Lin, Fred K. Friedman, Lyndon Chie, Denise L. Chung et al. · 2005 · Biochemistry
45. ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity
    Yongping Shao, Andrew E. Aplin · 2012 · Cell Death and Disease
46. Regulation of c-Raf Stability through the CTLH Complex
    Christina J. McTavish, Wesley Bérubé-Janzen, Xu Wang, Matthew E. R. Maitland, Louisa M. Salemi, David A. Hess, Caroline Schild‐Poulter · 2019 · International Journal of Molecular Sciences
47. Ras-induced serine phosphorylation of the focal adhesion protein paxillin is mediated by the Raf→MEK→ERK pathway
    Melissa Woodrow · 2003 · Experimental Cell Research
48. Regulation of SPIN90 Phosphorylation and Interaction with Nck by ERK and Cell Adhesion
    Chol Seung Lim, Sung Hyun Kim, Jin Gyoung Jung, Jin Kyu Kim, Woo Keun Song · 2003 · Journal of Biological Chemistry
49. Involvement of mitogen-activated protein kinase in the cytokine-regulated phosphorylation of transcription factor GATA-1
    Masayuki Towatari, Marco Cirò, Sergio Ottolenghi, Shinobu Tsuzuki, Tariq Enver · 2004 · The Hematology Journal
50. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity
    Caroline M. Emery, Kelli‐Ann Monaco, Ping Wang, Marissa N. Balak, Alyson K. Freeman, Jodi Meltzer, Scott M. Delach, Daniel P. Rakiec, David A. Ruddy, Joshua M. Korn et al. · 2017 · Molecular Cancer Research
51. Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2
    Andrew M. Kidger, Joanne M. Munck, Harpreet Kaur Saini, Kathryn Balmanno, Emma Minihane, Aurélie Courtin, Brent L. Graham, Marc O’Reilly, Richard Odle, Simon J. Cook · 2019 · Molecular Cancer Therapeutics
52. KSR--A Regulator and Scaffold Protein of the MAPK Pathway
    Thomas Raabe, Ulf Rüdiger Rapp · 2002 · Science s STKE
53. Advances in Molecular Biology of Lung Disease
    Claire Rooney, Tariq Sethi · 2015 · CHEST Journal
54. Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer
    Jinghua Pan, Hong Ke Zhou, Sheng-bin Zhu, Jin-lian Huang, Xiao-xu Zhao, Hui Ding, Yun-long Pan · 2018 · Cancer Management and Research
55. Complexity in KSR function revealed by Raf inhibitor and KSR structure studies
    Melissa McKay, Alyson K. Freeman, Deborah K. Morrison · 2011 · Small GTPases
56. Phosphorylation of TMEM55B by Erk/MAPK regulates lysosomal positioning
    Takemasu, Shinya, Nigorikawa, Kiyomi, Yamada, Miho, Tsurumi, Go, Kofuji, Satoshi, Takasuga, Shunsuke, Hazeki, Kaoru · 2019 · The Journal of Biochemistry
57. The identification of potent, selective and CNS penetrant furan-based inhibitors of B-Raf kinase
    Andrew K. Takle, Mark J. Bamford, Susannah Davies, Robert P. Davis, David K. Dean, Alessandra Gaiba, Elaine A Irving, Frank D. King, A. Naylor, Christopher A. Parr et al. · 2008 · Bioorganic & Medicinal Chemistry Letters
58. Ablation of BRaf Impairs Neuronal Differentiation in the Postnatal Hippocampus and Cerebellum
    Verena Pfeiffer, Rudolf Götz, Chaomei Xiang, Guadelupe Camarero, Attila Braun, Yina Zhang, Robert Blum, Helmut Heinsen, Bernhard Nieswandt, Ulf Rüdiger Rapp · 2013 · PLoS ONE
59. MAPK Signaling Pathway Regulates p27 Phosphorylation at Threonin 187 as Part of the Mechanism Triggered by Early-Weaning to Induce Cell Proliferation in Rat Gastric Mucosa
    Luciana H. Osaki, Patrı́cia Gama · 2013 · PLoS ONE
60. Inhibition of extracellular signal-regulated kinase (ERK) activity with SL327 does not prevent acquisition, expression, and extinction of ethanol-seeking behavior in mice
    Peter A. Groblewski, Frederick H. Franken, Christopher L. Cunningham · 2010 · Behavioural Brain Research
61. Crucial requirement of ERK/MAPK signaling in respiratory tract development
    Olivier Boucherat, Valérie Nadeau, Félix‐Antoine Bérubé‐Simard, Jean Charron, Lucie Jeannotte · 2015 · Development
62. BAD Contributes to RAF-mediated Proliferation and Cooperates with B-RAF-V600E in Cancer Signaling
    Lisa Polzien, Angela Baljuls, Marco Albrecht, Mirko Hekman, Ulf Rüdiger Rapp · 2011 · Journal of Biological Chemistry
63. Abstract 4973: Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations
    Shripad V. Bhagwat, William T. McMillen, Shufen Cai, Baohui Zhao, Matthew Whitesell, Lisa J. Kindler, Robert Stephen Flack, Wenjuan Wu, Karen Huss, Bryan D. Anderson et al. · 2017 · Cancer Research
64. AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
    Rui Ma, Ling Xu, Xiujuan Qu, Xiaofang Che, Ye Zhang, Yibo Fan, Ce Li, Tianshu Guo, Kezuo Hou, Xuejun Hu et al. · 2018 · British Journal of Cancer
65. The neuronal adaptor protein Fe65 is phosphorylated by mitogen-activated protein kinase (ERK1/2)
    Claire L. Standen, Michael S. Perkinton, Helen L. Byers, Sashi Kesavapany, Kwok‐Fai Lau, Malcolm Andrew Ward, Declan M. McLoughlin, Christopher C.J. Miller · 2003 · Molecular and Cellular Neuroscience
66. Absence of BRAF Gene Mutation in Non-Melanoma Skin Tumors
    Massimo Libra, Grazia Malaponte, Valentina Bevelacqua, Roberta Siciliano, Paola Castrogiovanni, Alberto Fulvi, Giuseppe Micali, Giovanni Ligresti, María Clorinda Mazzarino, Franca Stivala et al. · 2006 · Cell Cycle
67. The Resorcylic Acid Lactone Hypothemycin Selectively Inhibits the Mitogen-Activated Protein Kinase Kinase-Extracellular Signal-Regulated Kinase Pathway in Cells
    Hidesuke Fukazawa, Yoshimi Ikeda, Mari Fukuyama, Takeshi Suzuki, Hiroshi Hori, Tôru Okuda, Yoshimasa Uehara · 2010 · Biological and Pharmaceutical Bulletin
68. Inflammatory side effects of BRAF and MEK inhibitors
    Anna G. Mackin, Paula E. Pecen, Amanda L. Dinsmore, Jennifer L. Patnaik, Rene C. Gonzalez, William Allen Robinson, Alan Gary Palestine · 2019 · Melanoma Research
69. TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis
    Anny Shai, David L. Dankort, Joseph M. Juan, Shon Green, Martin McMahon · 2015 · Cancer Research
70. Gastrointestinal cancer - only a deregulation of stem cell differentiation? (Review)
    Daniel Neureiter, C. Herold, Matthias Ocker · 2006 · International Journal of Molecular Medicine
71. Abstract 5168: KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors
    Francis J. Burrows, Linda V. Kessler, Jeffrey W. Chen, Xin Gao, Rasmus Hansen, Shuangwei Li, Carol Thach, Levan Darjania, Yvonne Yao, Yi Wang et al. · 2017 · Cancer Research
72. A patent review of RAF kinase inhibitors (2010–2018)
    Ruo‐Jun Man, Yaliang Zhang, Ai-Qin Jiang, Hai‐Liang Zhu · 2019 · Expert Opinion on Therapeutic Patents
73. A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours
    David Jamieson, Melanie J. Griffin, Julieann Sludden, Yvette Drew, Nicola Cresti, Karen E. Swales, Mark Merriman, Rodger A. Allen, Paul Bevan, Markus Buerkle et al. · 2016 · European Journal of Cancer
74. New insights into RSK activation and hematopoietic cancer.
    A. Cuadrado, A. Nebreda · 2007 · Cancer Cell
75. ERK and miRNA-1 target Cx43 expression and phosphorylation to modulate the vascular protective effect of angiotensin II
    Yan Lei, Xiaoyong Peng, Tao Li, Liangming Liu, Guangming Yang · 2018 · Life Sciences
76. Phosphorylation of Grb10 by Mitogen-Activated Protein Kinase: Identification of Ser150 and Ser476 of Human Grb10ζ as Major Phosphorylation Sites
    Paul R. Langlais, Changhua Wang, Lily Dong, Christopher A. Carroll, Susan T. Weintraub, Feng Liu · 2005 · Biochemistry
77. Direct interaction and N-terminal phosphorylation of c-Jun by c-Mil/Raf.
    Gerald Radziwill, Monika Niehof, Christian Rommel, Karin Moelling · 1995 · Proceedings of the National Academy of Sciences
78. Abstract 1304: Clinical pharmacokinetics of GDC-0973, an oral MEK inhibitor, in cancer patients: data from a Phase 1 study
    Luna C. Musib, Steve Eppler, Edna F. Choo, Alan Deng, Dale Miles, Bih Hsiung. Hsu, Lee S. Rosen, Branimir Ivan Sikic, Patricia Mucci LoRusso, Wen Ma et al. · 2011 · Cancer Research
79. Structure–activity relationship study of DEL-22379: ERK dimerization inhibitors with increased safety
    Yang Yang, Yuanzheng Zhou, Lei Tao, Tao Yang, Yinglan Zhao, Youfu Luo · 2020 · Molecular Diversity
80. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression
    Lucy Lee, Huifeng Niu, Petra Goelzer, Ruediger Rueger, Jonathan Deutsch, Rachel Busse‐Reid, Stefanie DeSchepper, Steve Blotner, Joanne Barrett, Georges Weissgerber et al. · 2010 · The Journal of Clinical Pharmacology
81. Phosphorylation of the C-Terminal Domain of RNA Polymerase II by the Extracellular-Signal-Regulated Protein Kinase ERK2
    Rhea-Beth Markowitz, April S. Hermann, D.F. Taylor, L.Y. He, Spencer J. Anthony‐Cahill, Natalie G. Ahn, William S. Dynan · 1995 · Biochemical and Biophysical Research Communications
82. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF V600E mutant cancer
    Sung Pyo Hong, Soon Kil Ahn · 2017 · Life Sciences
83. A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling
    Monique J. Kauke, Alison W. Tisdale, Ryan L. Kelly, Christian Joerg Braun, Michael T. Hemann, Karl Dane Wittrup · 2018 · Molecular Cancer Therapeutics
84. Dual RAF–MEK Inhibitor Assessed
    2020 · Cancer Discovery
85. Transcriptional Repression Activity of N-MYCProtein Requires Phosphorylation by MAP Kinase
    Akira Manabe, Sanae M.M. Iguchi‐Ariga, Hajime Iizuka, Hiroyoshi Ariga · 1996 · Biochemical and Biophysical Research Communications
86. Abstract 2517: Pharmacodynamic biomarkers for ARQ 736, a small molecule BRAF inhibitor
    Yi Yu, Xiaolan Zhao, Xiubin Gu, Edward Q. Chang, Laura A. Cousens, Erin Chiesa, Deirdre Lowe, Yanbin Liu, Cathy O. Bull, Carol G. Waghorne et al. · 2010 · Cancer Research
87. Abstract 2606: Antitumor activity of the selective RAF inhibitor HM95573 in melanoma
    InHwan Bae, Young‐Gil Ahn, Namgoong GwangMo, SuHyeon Kim, Jiyeon Song, Taehun Song, Jae Ho Lee, Kyuhang Lee, Youngmi Lee, Younghoon Kim et al. · 2015 · Cancer Research
88. Abstract C146: Combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 inhibits the growth of BRAF mutant and RAS mutant preclinical models of melanoma and CRC.
    Elizabeth Carideo Cunniff, Julie Zhang, Jouhara Chouitar, Jerome Thomas Mettetal, Kazuhide Nakamura, Takeo Arita, Akito Nakamura, Masanori Okaniwa, Tomoyasu Ishikawa, Sei Yoshida et al. · 2013 · Molecular Cancer Therapeutics
89. Abstract LB-114: RAF inhibitor LXH254 effectively inhibits B-and-CRAF, but not ARAF
    Kelli‐Ann Monaco, Scott M. Delach, Paul Fordjour, Salonee Parikh, Yun Feng, Mariela Jaskelioff, Darrin D. Stuart, Giordano Caponigro · 2019 · Cancer Research